Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Prothena Corp (NQ: PRTA )

14.44 +0.04 (+0.28%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Prothena Corp

< Previous 1 2 3 4 5 6 Next >
Expert Ratings For Prothena Corp
Via Benzinga
Earnings Scheduled For November 12, 2024
Via Benzinga
Earnings Preview For Prothena Corp
Via Benzinga
PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday
Via Benzinga
Breaking Down Prothena Corp: 4 Analysts Share Their Views
Via Benzinga
Dow Dips 300 Points; Emcore Shares Spike Higher
Via Benzinga
Topics Stocks
Exposures US Equities
Demystifying Prothena Corp: Insights From 8 Analyst Reviews
Via Benzinga
Decoding 6 Analyst Evaluations For Prothena Corp
Via Benzinga
Prothena Corp: Q4 Earnings Insights
Via Benzinga
Earnings Scheduled For February 15, 2024
Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Crude Oil Moves Higher; Prime Medicine Shares Spike Higher
Via Benzinga
Exposures Fossil Fuels
PRTA Stock Earnings: Prothena Corp Beats EPS, Beats Revenue for Q2 2024
PRTA stock results show that Prothena Corp beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Eli Lilly Drags Alzheimer's Stocks Prothena, Eisai Lower Despite FDA Win
An FDA panel unanimously backed Eli Lilly's Alzheimer's drug, but shares of Lilly and its rivals fell Tuesday. 
Via Investor's Business Daily
Exposures Product Safety
PRTA Stock Earnings: Prothena Corp Misses EPS, Misses Revenue for Q1 2024
PRTA stock results show that Prothena Corp missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Earnings Outlook For Prothena Corp
Via Benzinga
Navigating 5 Analyst Ratings For Prothena Corp
Via Benzinga
$100 Invested In Prothena Corp 5 Years Ago Would Be Worth This Much Today
Via Benzinga
Demystifying Prothena Corp: Insights From 5 Analyst Reviews
Via Benzinga
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting. 
Via Investor's Business Daily
Exposures Product Safety
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Hewlett Packard Enterprise, Hologic And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow Jones futures falling around 100 points on Tuesday. Shares of Hewlett Packard Enterprise Company (NYSE: HPE) shares fell sharply in pre-market... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
4 Analysts Have This to Say About Prothena Corp
Via Benzinga
Why UPS Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of United Parcel Service, Inc. (NYSE: UPS) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter sales results and issued FY24 sales 
Via Benzinga
Boeing, Pacific Biosciences of California And Other Big Stocks Moving Lower On Monday
U.S. stocks traded mixed, with the Dow Jones index falling around 80 points on Monday. Shares of The Boeing Company (NYSE: BA) fell during Friday’s session after an exit door blew out of a 737 aircraft... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of RxSight, Inc. (NASDAQ: RXST) rose sharply during Monday’s session after the company issued preliminary FY23 and FY24 revenue guidance above estimates. Also, Needham maintained a Buy rating on... 
Via Benzinga
Alzheimer's Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And Others
Recent advancements in Alzheimer's disease treatments targeting the removal of toxic proteins (white matter) from the brain have sparked a renewed interest in developing vaccines to combat this  
Via Benzinga
Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning
Biotech companies are edging closer to finding the answers behind Alzheimer's disease. 
Via Investor's Business Daily
8 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.